Also found in: Wikipedia.


(my-ka-fun-gin) ,


(trade name)


Therapeutic: antifungals
Pharmacologic: echinocandins
Pregnancy Category: C


Esophageal candidiasis.Candidemia/acute disseminated candidiasis/Candidal peritonitis and abscesses.Prophylaxis of Candida infections during hematopoetic stem cell transplantation.


Inhibits synthesis of glucan required for the formation of fungal cell wall.

Therapeutic effects

Death of susceptible fungi.
Active against the following Candida spp.: C. albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis.


Absorption: IV administration results in complete bioavailability.
Distribution: Unknown.
Protein Binding: >99 %.
Metabolism and Excretion: Mostly metabolized; 71% fecal elimination.
Half-life: 15 hr.

Time/action profile

IVrapidend of infusion24 hr


Contraindicated in: Hypersensitivity.
Use Cautiously in: Severe hepatic impairment; Obstetric: Use only if clearly needed; Lactation / Pediatric: Children <4 mo (safety not established).

Adverse Reactions/Side Effects


  • worsening hepatic function/hepatitis


  • renal impairment


  • hemolysis/hemolytic anemia


  • injection site reactions


  • allergic reactions including anaphylaxis (rare) (life-threatening)


Drug-Drug interaction

↑ blood levels and risk of toxicity with sirolimus and nifedipine (dose adjustments may be necessary).


Intravenous (Adults) Esophageal candidiasis–150 mg daily for 15 days (range 10–30 days); Candidemia/acute disseminated candidiasis/Candida peritonitis and abscesses—100 mg daily for 15 days (range 10–47 days); Prevention of Candida infections in stem cell transplantation—50 mg daily (duration range 6–51 days).
Intravenous (Children ≥4 mo and >30 k g) Esophageal candidiasis–2.5 mg/kg daily (maximum daily dose = 150 mg); Candidemia/acute disseminated candidiasis/Candida peritonitis and abscesses—2 mg/kg daily (maximum daily dose = 100 mg); Prevention of Candida infections in stem cell transplantation—1 mg/kg daily (maximum daily dose = 50 mg)
Intravenous (Children ≥4 mo and ≤30 kg) Esophageal candidiasis–3 mg/kg daily; Candidemia/acute disseminated candidiasis/Candida peritonitis and abscesses—2 mg/kg daily; Prevention of Candida infections in stem cell transplantation—1 mg/kg daily
Intravenous (Neonates) 7–10 mg/kg daily. Higher dose should be used in neonates <27 weeks gestation and those with meningitis.


Lyophilized powder for injection: 50 mg/vial, 100 mg/vial

Nursing implications

Nursing assessment

  • Assess symptoms of esophageal candidiasis (dysphagia, odynophagia, retrosternal pain) prior to and during therapy.
  • Monitor for signs of anaphylaxis (rash, pruritus, wheezing, laryngeal edema, abdominal pain). Discontinue micafungin and notify health care professional immediately if these occur.
  • Assess for injection site reactions (phlebitis, thrombophlebitis) during therapy. These occur more frequently in patients receiving micafungin via peripheral IV infusion.
  • Lab Test Considerations: May cause ↑ serum alkaline phosphatase, bilirubin, ALT, AST, and LDH levels. If elevations occur, monitor for worsening liver function; may require discontinuation of therapy.
    • May cause ↑ BUN and serum creatinine.
    • May cause leukopenia, neutropenia, thrombocytopenia, and anemia. Monitor for worsening levels; may require discontinuation of therapy.
    • May cause hypokalemia, hypocalcemia, and hypomagnesemia.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • Intravenous Administration
  • Intermittent Infusion: Diluent: For Adults: Reconstitute each 50-mg vial with 5 mL of 0.9% NaCl or D5W to achieve concentration of 10 mg/mL. Reconstitute each 100-mg vial with 5 mL of 0.9% NaCl or D5W to achieve concentration of 20 mg/mL. Dissolve by gently swirling vial; do not shake vigorously. Directions for further dilution based on indication for use. For prophylaxis of Candida infections, add 50 mg of micafungin to 100 mL of 0.9% NaCl or D5W. For treatment of esophageal candidiasis, add 150 mg of micafungin to 100 mL of 0.9% NaCl or D5W. Reconstituted vials and infusion are stable for 24 hr at room temperature. Protect diluted solution from light.Concentration: 0.5–1.5 mg/mL.
  • For Children: Determine dose and divide by final concentration (10 or 20 mg/mL). Add withdrawn volume to 0.9% NaCl or D5W in IV bag or syringe. Concentration: 0.5 mg/mL–4 mg/mL. Concentrations >1.5 m g/mL should be administered via central venous catheter to minimize infusion reactions. Discard unused vials.
  • Rate: Flush line with 0.9% NaCl prior to administration. Infuse over 1 hr. More rapid infusions may result in more frequent histamine mediated reactions.
  • Y-Site Compatibility: aminophylline, bumetanide, calcium chloride, calcium gluconate, carboplatin, cyclosporine, dopamine, doripenem, eptifibatide, esmolol, rtoposide, fenoldopam, furosemide, heparin, hydromorphone, lidocaine, lorazepam, magnesium sulfate, mesna, milrinone, nitroglycerin, nitroprusside, norepinephrine, phenylephrine, potassium chloride, potassium phosphates, sodium phosphates, tacrolimus, theophylline, vasopressin
  • Y-Site Incompatibility: amiodarone, cisatracurium, diltiazem, dobutamine, epinephrine, insulin, labetalol, levofloxacin, meperidine, midazolam, morphine, mycophenolate mofetil, nesiritide, nicardipine, octreotide, ondansetron, phenytoin, rocuronium, telavancin, vecuronium

Patient/Family Teaching

  • Inform patient of the purpose of micafungin.
  • Advise patient to notify health care professional immediately if signs of anaphylaxis occur.

Evaluation/Desired Outcomes

  • Resolution of signs and symptoms of esophageal candidiasis, candidemia, acute disseminated candidiasis, candidal peritonitis and abscesses.
  • Prevention of Candida infections during hematopoetic stem cell transplantation.


a systemic antifungal.
indications This drug is used in the treatment of esophageal candidiasis and susceptible candida species (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, and C. tropicalis) and in prophylaxis of candida infections in patients undergoing hepatopoietic stem cell transplantation.
contraindications Known hypersensitivity to this drug or to other ecinocandins prohibits its use.
adverse effects Adverse effects of this drug include dizziness, flushing, hypertension, phlebitis, abdominal pain, hypokalemia, hypocalcemia, and hypomagnesemia. Life-threatening side effects include seizures, neutropenia, thrombocytopenia, leukopenia, coagulopathy, anemia, and hemolytic anemia. Common side effects include headache; somnolence; nausea; anorexia; vomiting; diarrhea; increased aspartate aminotransferase, alanine aminotransferase, alkaline phosphate, and blood dehydrogenase; hyperbilirubinemia; rash; pruritus; injection site pain; and rigors.


An echinocandin-type antifungal with better pharmacokinetics than amphotericin B and itraconazole.

Candida species infections: candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses.

Via CYP3A4.


An echinocandin antifungal drug active against both Candida and Aspergillus species of fungi. The drug function by inhibiting fungal wall synthesis, an action without relevance for mammalian cells, and is thus of low toxicity. It has been found effective in the management of candidaemia and invasive candidosis.
References in periodicals archive ?
kefyr, predominantly among patients with hematologic malignancies, is in agreement with the results of another recent report (12), in which the increase was also attributed to the increasing use of the echinocandin drug micafungin.
Blood cultures grew Candida albicans and vancomycin-resistant enterococcus, for which he was treated with amphotericin B 300 mg intravenous daily, linezolid 600 mg intravenous twice daily, micafungin 100 mg intravenous daily, and piperacillin/tazobactam 2.
Other useful agents may be voriconazole (VFend), caspofungin (Cancidas), micafungin (Mycamine), or posaconazole (Noxafil).
Intravenous liposomal amphotericin B, intravenous echinocandins such as caspofungin and micafungin, and oral triazoles such as posaconazole and itraconazole can be used as alternative (salvage) therapy.
MYCAMINE is contraindicated in patients with known hypersensitivity to micafungin sodium, any component of MYCAMINE, or other echinocandins.
In the TENPIN (Liver Transplant EuropeaN Study Into the Prevention of Fungal INfection) study, the first randomised controlled trial of an echinocandin in this setting and the largest study of its kind, micafungin proved to be at least as effective as centre-specific standard of care (fluconazole, liposomal amphotericin B or caspofungin) in the prevention of invasive fungal infections in liver transplant patients.
Not only could MALDI-TOF MS reduce this process from days to hours, but the antifungal susceptibility test can give clinicians and the microlab a way of quickly learning that the strain is resistant to fluconazole and other members of the Triazole anti-fungal family of drugs, allowing them to go directly to micafungin or other Echinocandin anti-fungal drugs that work by an entirely different mechanism of action that is effective against the fluconazole-resistant fungus.
Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.
The news comes a week after GSK's Indian subsidiary signed a licensing agreement with Japanese company Astellas for exclusive rights to anti-fungal agent Micafungin in India.
SAN FRANCISCO -- Intravenous micafungin at two different doses produced cure rates similar to those with caspofungin in an international trial with 593 adults who had candidemia or invasive candidiasis, Dr.
As for share of each variety, China's top 5 antifungal drugs in 2011 were separately Voriconazole, Fluconazole, Caspofungin, Itraconazole and Micafungin, amounting to 88.